SG11202009866XA - Compositions and methods for cancer or neoplasia assessment - Google Patents
Compositions and methods for cancer or neoplasia assessmentInfo
- Publication number
- SG11202009866XA SG11202009866XA SG11202009866XA SG11202009866XA SG11202009866XA SG 11202009866X A SG11202009866X A SG 11202009866XA SG 11202009866X A SG11202009866X A SG 11202009866XA SG 11202009866X A SG11202009866X A SG 11202009866XA SG 11202009866X A SG11202009866X A SG 11202009866XA
- Authority
- SG
- Singapore
- Prior art keywords
- neoplasia
- assessment
- cancer
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656820P | 2018-04-12 | 2018-04-12 | |
| PCT/US2019/026395 WO2019199696A1 (fr) | 2018-04-12 | 2019-04-08 | Compositions et méthodes d'évaluation et de traitement d'un cancer ou d'une néoplasie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009866XA true SG11202009866XA (en) | 2020-11-27 |
Family
ID=68163272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009866XA SG11202009866XA (en) | 2018-04-12 | 2019-04-08 | Compositions and methods for cancer or neoplasia assessment |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210388445A1 (fr) |
| EP (1) | EP3775290A4 (fr) |
| JP (1) | JP2021520809A (fr) |
| KR (1) | KR20210003795A (fr) |
| CN (1) | CN112352057A (fr) |
| AU (1) | AU2019253569A1 (fr) |
| CA (1) | CA3096668A1 (fr) |
| SG (1) | SG11202009866XA (fr) |
| TW (1) | TW202012638A (fr) |
| WO (1) | WO2019199696A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020069350A1 (fr) | 2018-09-27 | 2020-04-02 | Grail, Inc. | Marqueurs de méthylation et panels de sondes de méthylation ciblées |
| US11795495B1 (en) * | 2019-10-02 | 2023-10-24 | FOXO Labs Inc. | Machine learned epigenetic status estimator |
| CA3154354A1 (fr) * | 2019-10-31 | 2021-05-06 | William R. Taylor | Detection du cancer de l'ovaire |
| US20230002832A1 (en) * | 2019-11-27 | 2023-01-05 | Keio University | Upper urinary tract urothelial carcinoma identification method |
| CA3173044A1 (fr) * | 2020-03-20 | 2021-09-23 | Singlera Health Technologies (Shanghai) Ltd. | Procedes et kits pour le depistage d'un neoplasme colorectal |
| WO2023096674A1 (fr) * | 2021-11-23 | 2023-06-01 | Pleno, Inc. | Dosages codés |
| WO2023116593A1 (fr) * | 2021-12-20 | 2023-06-29 | 江苏鹍远生物技术有限公司 | Procédé d'essai tumoral et application |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2299520T3 (es) * | 2000-09-01 | 2008-06-01 | Epigenomics Ag | Procedimiento para la determinacion del grado de metilacion de determinadas citosinas en dna genomico en el contexto secuencial 5'-cpg-3'. |
| EP2474628B1 (fr) * | 2007-02-21 | 2015-10-28 | Oslo Universitetssykehus HF | Nouveaux marqueurs du cancer |
| WO2008143896A1 (fr) * | 2007-05-14 | 2008-11-27 | The Johns Hopkins University | Marqueurs de méthylation pour cancer de la prostate et procédés d'utilisation |
| US7843254B2 (en) * | 2007-10-31 | 2010-11-30 | Texas Instruments Incorporated | Methods and apparatus to produce fully isolated NPN-based bandgap reference |
| WO2009108917A2 (fr) * | 2008-02-29 | 2009-09-03 | Oncomethylome Sciences, S.A. | Marqueurs pour la détection améliorée du cancer du sein |
| WO2011112845A2 (fr) * | 2010-03-11 | 2011-09-15 | Board Of Regents, The University Of Texas System | Méthodes et compositions associés à un essai de méthylation multiple pour prédire l'évolution de l'état de santé d'un patient |
| US10941449B2 (en) * | 2012-05-18 | 2021-03-09 | Clinical Genomics Pty. Ltd. | Method of screening for colorectal cancer |
| GB2526736A (en) * | 2013-02-21 | 2015-12-02 | Toma Biosciences Inc | Methods, compositions, and kits for nucleic acid analysis |
| EP2886659A1 (fr) * | 2013-12-20 | 2015-06-24 | AIT Austrian Institute of Technology GmbH | Méthylation de gène basée sur le diagnostic du cancer colorectal |
| EP3224377B1 (fr) * | 2014-11-25 | 2020-01-01 | AIT Austrian Institute of Technology GmbH | Diagnostic du cancer du poumon |
| EP3262191B2 (fr) * | 2015-02-24 | 2023-06-14 | Zymo Research Corporation | Dosages pour déterminer la méthylation de l'adn et marqueurs de méthylation de l'adn du cancer |
| EP3350344A1 (fr) * | 2015-09-17 | 2018-07-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Méthodes de détection du cancer |
| WO2017192221A1 (fr) * | 2016-05-05 | 2017-11-09 | Exact Sciences Corporation | Détection de néoplasie pulmonaire par analyse d'adn méthylé |
-
2019
- 2019-04-08 WO PCT/US2019/026395 patent/WO2019199696A1/fr active Application Filing
- 2019-04-08 JP JP2020555453A patent/JP2021520809A/ja active Pending
- 2019-04-08 KR KR1020207032480A patent/KR20210003795A/ko active Search and Examination
- 2019-04-08 AU AU2019253569A patent/AU2019253569A1/en active Pending
- 2019-04-08 EP EP19785565.3A patent/EP3775290A4/fr active Pending
- 2019-04-08 SG SG11202009866XA patent/SG11202009866XA/en unknown
- 2019-04-08 US US17/066,144 patent/US20210388445A1/en active Pending
- 2019-04-08 CN CN201980039559.6A patent/CN112352057A/zh active Pending
- 2019-04-08 CA CA3096668A patent/CA3096668A1/fr active Pending
- 2019-04-12 TW TW108112820A patent/TW202012638A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3096668A1 (fr) | 2019-10-17 |
| US20210388445A1 (en) | 2021-12-16 |
| EP3775290A4 (fr) | 2021-12-29 |
| TW202012638A (zh) | 2020-04-01 |
| JP2021520809A (ja) | 2021-08-26 |
| KR20210003795A (ko) | 2021-01-12 |
| WO2019199696A1 (fr) | 2019-10-17 |
| EP3775290A1 (fr) | 2021-02-17 |
| CN112352057A (zh) | 2021-02-09 |
| AU2019253569A1 (en) | 2020-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006627B (en) | Methods and compositions for treating cancer | |
| IL277079A (en) | Cartirin preparations and methods of use | |
| IL269150A (en) | Preparations and methods for the treatment of cancer | |
| SG11202009866XA (en) | Compositions and methods for cancer or neoplasia assessment | |
| ZA202003849B (en) | Vcar compositions and methods for use | |
| IL276808A (en) | Preparations and methods for the treatment of cancer | |
| EP3687981A4 (fr) | Compositions et méthodes de traitement du cancer | |
| IL283625A (en) | Diagnostic methods and preparations for cancer immunotherapy | |
| IL268815A (en) | Preparations and methods for transduction | |
| IL271326A (en) | Compositions and methods for enhancing radiotherapy in cancer | |
| IL274837A (en) | Methods and preparations for the treatment of cancer | |
| IL269157A (en) | Preparations and methods for the treatment of cancer | |
| IL271680A (en) | Compositions and methods for inhibiting expression of HMGB1 | |
| EP3612222A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
| EP3600302A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
| ZA202001572B (en) | Risk determination for neoplasia and cancer | |
| SG11202012435UA (en) | Compositions and methods for treating cancer | |
| IL260301A (en) | Preparations and methods for assessing the risk of cancer formation | |
| IL283076A (en) | Methods and preparations for cancer immunotherapy | |
| EP3714043A4 (fr) | Compositions et méthodes pour traiter le cancer | |
| EP3585398A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
| SG11202106295WA (en) | Compositions and methods for cancer therapy | |
| EP3727452A4 (fr) | Compositions et méthodes de traitement de la néoplasie | |
| EP3717502A4 (fr) | Compositions et procédés de caractérisation du cancer | |
| EP3688023A4 (fr) | Méthodes et compositions pour le traitement du cancer |